NCT05644769

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

The Chymase Angiotensin-(1-12) Axis in Hypertensive Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Trinity Hypertension & Metabolic Research Institute · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Determine the presence of the human sequence of Angiotensin-(1-12) in plasma of ten untreated hypertensive subjects and after 4 week with Lisinopril 40 mg every day. Determine the blood pressure reduction with Lisinopril 40mg.

Detailed description

Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients at baseline and after 4 weeks on Lisinopril 40mg every day. Measure concentrations of Ang-(1-12) in either spot urine collections from ten male and female hypertensive patients at baseline and after 4 weeks of Lisinopril 40mg every day.

Conditions

• Hypertension

Interventions

Type	Name	Description
OTHER	Determine the presence of Human sequence Ang-(1-12) on no medication	Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
DRUG	Human sequence Ang-(1-12) on Lisinopril 40mg every day	Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.

Timeline

• Start date: 2022-11-15
• Primary completion: 2023-03-31
• Completion: 2023-03-31
• First posted: 2022-12-09
• Last updated: 2022-12-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study